KROS Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
40.0M
0
-100.0%
367.0K
-4.7%
385.0K
-97.3%
14.3M
Cost of Revenue
0
0
0
0
0
Gross Profit
40.0M
0
-100.0%
367.0K
-4.7%
385.0K
-97.3%
14.3M
Operating Expenses
27.2M
-12.1%
30.9M
+17.9%
26.2M
-11.5%
29.7M
+0.0%
29.6M
R&D
20.5M
-8.2%
22.3M
+38.7%
16.1M
-10.1%
17.9M
-8.2%
19.5M
SG&A
6.7M
-22.1%
8.6M
-15.2%
10.1M
-13.6%
11.7M
+16.0%
10.1M
Operating Income
12.8M
+141.4%
-30937000
-19.6%
-25877000
+11.6%
-29270000
-90.3%
-15384000
EBITDA
13.2M
+143.2%
-30535000
-19.9%
-25474000
+11.8%
-28870000
-92.6%
-14989000
Net Income
14.2M
+149.3%
-28710000
-21.1%
-23708000
-1.1%
-23461000
-222.3%
-7280000
EPS (Basic)
$0.71
+149.0%
$-1.45
-19.8%
$-1.21
-39.1%
$-0.87
-383.3%
$-0.18
EPS (Diluted)
$0.70
+148.3%
$-1.45
-19.8%
$-1.21
-51.2%
$-0.80
-344.4%
$-0.18
Shares (Diluted)
20.3M
+2.7%
19.8M
+0.9%
19.6M
-32.7%
29.2M
-28.2%
40.6M
Keros Therapeutics (KROS) — Financials